Equity
-€6.1m
Debts exceed assets in financial year 2025.
BETA - CELL
Lifetime
20 annual accounts with figures on one time axis, 27 filings since 1999peak €880,614 (2024)
€17,043▼ 98.1%
lowest -€1.7m (2016)
-€139,294▼ €520,481
peak €720,651 (2006)
-€6.1m▼ €139,294
€6.4m▲ 0.9%
peak 7.8 FTE (2018)
0.1 FTE▼ 94.7%
Board15 names since 2017all names
3 directorsBEFAS and 2 others
Owners3 names in the annual accounts
90.48%TAMORCO
Documentsfilings and deeds
14-07-202617 days before the deadline
2025financial year
Gross margin from €880,614 to €17,043Loss of €139,294Staff from 1.9 FTE to 0.1 FTE2 directors appointed, 2 resignations 08-07Cash from €43,242 to €1,974
Key points
from the 2025 annual accountsResult
-€139,294 -€139,294
From profit to loss in 2025, after a profit of €381,187 in 2024.
Turnover
≈ €120,000 estimated
The accounts state no turnover.
Debts
€6.4m 1,938% of the balance sheet
Financial debts 75%Suppliers 1%Taxes and wages 0%Other 24%
Of this, €47,977 falls due within a year.
Staff
0.1 FTE from 7.8 in 2018
Between 2018 and 2025, 99% of the full-time equivalents disappeared.
Position in the sector
-1838.2%
Lower solvency than 95% of companies in chemicals. Sector median 50.1% · 317 companies.
Checked score
54
Fair
Financially stronger than 35% of micro companies in chemicals (NACE 20)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.5% across 356 companies (NACE 20, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 4.6%highest value
01-2025: 4.6%● unchanged vs 12-2024highest value
02-2025: 4.6%● unchanged vs 01-2025highest value
03-2025: 4.5%▼ -0.1 percentage points vs 02-2025
04-2025: 4.5%● unchanged vs 03-2025
05-2025: 4.5%● unchanged vs 04-2025
06-2025: 4.3%▼ -0.2 percentage points vs 05-2025
07-2025: 4.3%● unchanged vs 06-2025
08-2025: 0.8%▼ -3.5 percentage points vs 07-2025
09-2025: 0.8%● unchanged vs 08-2025
10-2025: 0.8%● unchanged vs 09-2025
11-2025: 0.8%● unchanged vs 10-2025
12-2025: 0.8%● unchanged vs 11-2025
01-2026: 0.8%● unchanged vs 12-2025
02-2026: 0.8%● unchanged vs 01-2026
03-2026: 0.8%● unchanged vs 02-2026lowest value
04-2026: 0.9%▲ +0.1 percentage points vs 03-2026
05-2026: 0.9%● unchanged vs 04-2026
06-2026: 0.8%▼ -0.1 percentage points vs 05-2026
07-2026: 0.9%▲ +0.1 percentage points vs 06-2026
08-2026: 1.7%▲ +0.8 percentage points vs 07-2026
09-2026: 1.7%● unchanged vs 08-2026
10-2026: 1.7%● unchanged vs 09-2026
11-2026: 1.7%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Loss of €139,294 (financial year 2025)
Negative equity -€6.1m
lowers risk
Size: 0.1 FTE, total assets €330,384
Legal form: public limited company
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 20, micro). It does better than 9% of them on solvency, 47% on liquidity, 42% on profitability and 43% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,619 companies had the same profile as BETA - CELL has now. Each dot stands for 17 companies, two years later.
84.5%
were still trading
10.0%
stopped another way
4.5%
went bankrupt
Another 1.0% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of BETA - CELL itself: 1.7% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,619 companies, not a prediction for BETA - CELL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
No credit on open account
Liquidity is ample, with a current ratio of 5.84 (4.84 in 2024), above the usual 1.5. Short-term debt is 14.5% and cash 0.6% of total assets. However, equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€6.1m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-07-2026, 17 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
17 days early
2024
30 days early
2023
7 days early
2022
42 days early
2021
8 days late
2020
6 days late
2019
61 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 3 days before the deadline. In the sector (NACE 20), the median for financial year 2024 was 22 days before the deadline, and 26% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 14 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
B
BVJEMICONSULT
Managing director, LouisMACHIELS
- TAMORCO 90.48%equity €28.7m (2025) · 2025 annual accounts of TAMORCO
- OPUS 23.15%equity €87,116 (2024) · 2024 annual accounts of OPUS
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0465030668
2 directors appointed, 2 resignations
Resignations: OPUS and DUPONT Alain Gilbert · Permanent representative: PIPELEERS Daniel Guillaume Victor Henri · Appointments: COOREMAN Jan Baptist Louis Casimer Hilde Marie (class A director) and VALENZUELA SILVA Gonzalo (class A director) · General meeting of 26-06-2025 · Gazette deed
New director
Jan-Baptist Cooreman appointed, Kurt Daniels resigned · Permanent representative: Prakash ADVANI · Board meeting of 22-10-2024 · Gazette deed
Permanent representative: PrakashADVANI
Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BETA - CELL Diepenbeek | €0.3m | €17,043 | -1838.2% | 0.1 |
| APOTHEEK HAEMELS Tervuren | €0.5m | €136,956 | 37.8% | - |
| Kemira Waterchemie NV Aartselaar | €1.6m | €237,390 | 77.6% | 0.6 |
| beLife Engis | €2.9m | -€18,180 | 41.7% | - |
| Ack-X Ravels | €0.05m | €11,110 | 83.7% | - |
| AVROXA Ghent | €1.8m | €170,832 | 48.4% | 1 |
| ADDITYS Tournai | €1.3m | €550,114 | 46.2% | 1 |
These companies have the same main activity as BETA - CELL: manufacture of chemicals and chemical products (NACE 20140). They are comparable in size and age: total assets between €46,400 and €2.9m, founded between 1990 and 2020.
Official details
Source: KBO- Status
- Active since 30-12-1998Normal situation
- Registered office
- 13 active companies are registered at this addressSource: KBO register, as of 10 November 2026.
- Activity
- Manufacture of chemicals and chemical productsNACE 20140and 1 other
- Establishment unit
- 2.091.444.0213590 Diepenbeek, since 28-06-1999
- Financial year end
- 31 December
- Peppol
- Reachable since 23-01-2026
Annual accounts 2025
- €330,384▼ 19.9%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 14-07-2026, 17 days before the end of the filing period
Insights on BETA - CELL
BETA - CELL has existed since 1998. The gross margin fell from €880,614 in 2024 to €17,043 in 2025 and staff from 1.9 to 0.1 full-time equivalents.
Solvency fell in 2025 from -1438.2% to -1838.2% because of the loss and higher long-term debts.
TAMORCO holds 90.48% of the shares. In December 2024, three directors stepped down. In June 2024, the Official Gazette published the appointment of BVJEMICONSULT as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BETA - CELL
- What is the company number of BETA - CELL?
- The company number of BETA - CELL is 0465.030.668. The VAT number is the same number with BE in front: BE 0465.030.668.
- Where is BETA - CELL based?
- The registered office is at Agoralaan A Bis, 3590 Diepenbeek.Company details
- What does BETA - CELL do?
- According to the KBO register, the main activity is manufacture of chemicals and chemical products (NACE 20140).
- What is the legal form of BETA - CELL?
- BETA - CELL is a public limited company (NV).
- When was BETA - CELL founded?
- BETA - CELL was founded on 30-12-1998.
- Is BETA - CELL still active?
- Yes, BETA - CELL is an active enterprise in the KBO register.
- How many employees does BETA - CELL have?
- BETA - CELL had an average of 0.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of BETA - CELL?
- The turnover in financial year 2025 is ≈ €120,000. This figure is estimated from the gross margin of €17,043 and 2,728 comparable companies of the same size. It probably lies between €48,000 and €290,000. It is a rough estimate.
- Is BETA - CELL profitable?
- In financial year 2025, BETA - CELL made a loss of €139,294.
- Where can I find the annual accounts of BETA - CELL?
- BETA - CELL filed 27 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BETA - CELL due?
- BETA - CELL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.